Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. Our proprietary T-SPOT® technology platform allows us to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases.
Our first product is the T-SPOT.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test is the Company’s second product and the first in a series of products intended for the transplantation market. Overall, Oxford Immunotec has several active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. We are headquartered near Oxford, UK and in Marlborough, Mass.
Additional information can be found at www.oxfordimmunotec.com.